Marathon Pharmaceuticals to Charge $89,000 for Muscular Dystrophy Drug
Marathon Pharmaceuticals LLC says it will charge $89,000 annually in the U.S. for a decades-old steroidal drug that was approved for U.S. sale for the first time on Thursday, a price that is as much as 70 times higher than drug’s price overseas.
The U.S. Food and Drug Administration approved the drug, called deflazacort, on Thursday to treat a rare type of muscular dystrophy that affects some 12,000 boys in the U.S., most of whom die in their 20s and 30s. The drug isn’t a cure, but it has been shown to improve muscle strength compared with a placebo, the FDA said in a statement announcing the approval.
The drug hasn’t been sold in the U.S. previously, mainly because no company thought it would be profitable enough to warrant the effort of seeking FDA approval. But U.S. patients have been importing it from foreign countries since the 1990s after clinical trials showed its potential to reduce inflammation with fewer side effects than another steroid.
The price set by Marathon, based in Northbrook, Ill., is 50 to 70 times what most U.S. patients now pay to buy deflazacort from an online pharmacy in the United Kingdom, according to advocates for patients with Duchenne muscular dystrophy.
Christine McSherry of Pembroke, Mass., pays about $1,600 annually to buy deflazacort from the U.K. pharmacy for her son, Jett, she said.
But the pharmacy recently told customers it would stop shipping the drug to the U.S. after Marathon received FDA approval for its version.
Ms. McSherry, who runs Jett Foundation, a nonprofit aimed at Duchenne, said she is “disappointed that Marathon increased my cost for the drug by more than $87,000 a year.”
Marathon Chief Financial Officer Babar Ghias defended the price in an interview. He said the company will likely receive much less in net revenue than its $89,000 per patient list price, after providing discounts to government insurers and financial assistance to patients who can’t afford the drug.
The company will start selling the medicine under the brand name Emflaza in March, Mr. Ghias said.
Mr. Ghias, a former mergers and acquisitions banker, said the company showed restraint in how it priced the drug. Other new drugs for so-called orphan diseases, which affect fewer than 200,000 people nationally, have carried higher price tags, he said.
“It’s modestly priced for an orphan drug,” Mr. Ghias said.
Pharmaceutical companies are under mounting scrutiny for their pricing of drugs, many of which now approach or exceed $100,000 annually per patient. Many companies defend themselves by saying that their prices are needed to justify their large investments in discovering and developing new treatments.
Marathon gained clearance to sell deflazacort after licensing the rights to clinical trial data from the 1990s that hadn’t been fully analyzed. The FDA required the company to complete an analysis of the old trial data and conduct some new studies to gain approval, Mr. Ghias said.
Mr. Ghias declined to say how much Marathon spent to acquire the trial data or conduct original research. He said Marathon doesn’t expect to recoup its investment in the drug for several years. Marathon doesn’t have commitments yet from insurers that they will pay for the drug, Mr. Ghias said.
Pat Furlong, a patient advocate, said she hopes deflazacort will be widely covered by insurers now that it is FDA-approved. But she worries that the drug’s price could continue to keep it out of reach for patients with high-deductible insurance or whose insurance won’t pay for the drug at all, she says.
“I worry about what people have to pay out of pocket,” said Ms. Furlong, president of the nonprofit Parent Project Muscular Dystrophy.

"The price set by Marathon, based in Northbrook, Ill., is 50 to 70 times what most U.S. patients now pay to buy deflazacort from an online pharmacy in the United Kingdom, according to advocates for patients with Duchenne muscular dystrophy.
Christine McSherry of Pembroke, Mass., pays about $1,600 annually to buy deflazacort from the U.K. pharmacy for her son, Jett, she said.
But the pharmacy recently told customers it would stop shipping the drug to the U.S. after Marathon received FDA approval for its version."
When it comes to human healthcare, the most immoral, unethical country in the world is clearly the US.
Funny how everyone argues about repealing Obamacare, or replacing Obamacare, or how Obamacare is a disaster because cheap and worthless private coverage was eliminated and replaced with more expensive coverage that actually provides something. Yet if you post an article about the ROOT of the problem with US healthcare, nobody is interested. There is a reason why healthcare entitlements top the list of US federal expenditures, and nobody is interested in addressing it.
Big government is driving up the cost. The regulations that prevent people from buying it at the most competitive overseas cost should be eliminated. Open up the free market and buy it for less.
Lol - it costs 70 times more here than abroad. The free market couldn't possibly bring that in line no matter what.
Hal, you need to read the whole comment.
The regulations that prevent people from buying it at the most competitive overseas cost should be eliminated.
I agree, but Big Pharma isn't going to even try to compete with those prices. They've been lulled into the reality that the US is a cash cow, and the most vulnerable people here are allowed to be financially raped in order to finance an executive's yacht upgrade. The desire to stay alive is the leverage the pharmaceutical companies are using to empty the bank accounts of sick citizens.
Ah....Capitalism at it's best. MAGA
Would be laughable, Pj, if it weren't so pathetically true. Sickness is a big business in America. Recovery is not. The Medical-Pharma-Insurance conspiracy wants every single American, from birth, on some prescription drug.
Marathon Chief Financial Officer Babar Ghias defended the price in an interview. He said the company will likely receive much less in net revenue than its $89,000 per patient list price, after providing discounts to government insurers and financial assistance to patients who can’t afford the drug.
The company will start selling the medicine under the brand name Emflaza in March, Mr. Ghias said.
Mr. Ghias, a former mergers and acquisitions banker, said the company showed restraint in how it priced the drug. Other new drugs for so-called orphan diseases, which affect fewer than 200,000 people nationally, have carried higher price tags, he said.
“It’s modestly priced for an orphan drug,” Mr. Ghias said.
Pharmaceutical companies are under mounting scrutiny for their pricing of drugs, many of which now approach or exceed $100,000 annually per patient. Many companies defend themselves by saying that their prices are needed to justify their large investments in discovering and developing new treatments.
How many people CAN afford 89,000 dollars a year for one drug?
Everyone knows that eventually we will have national health care. Just do it now before more people go bankrupt or die because we don't like the word "socialized" before the "medicine."
National Health care isn't going to solve this problem.
Dear President Trump-- you said you would fix this, so, please, fix it.
Yes, definitely fix it. Why, it's been a whole three weeks and you still haven't fixed all of the country's problems. WHAT HAVE YOU BEEN DOING WITH YOUR TIME?????
More seriously, being able to buy such products in other countries with lower prices is the answer. The drug companies have a governmentally protected monopoly (all monopolies are protected by government or they couldn't exist) in this country. To break that monopoly, we must go outside the jurisdiction where it's protected to obtain the product.
Hal,
how Obamacare is a disaster because cheap and worthless private coverage was eliminated and replaced with more expensive coverage that actually provides something.
Except that, when you figure in the greatly increased costs attributable to government mandates (use of armed force), enormously increased deductibles and high level of co pays, it actually doesn't provide anything unless you have a totally catastrophic illness or injury. By then, you're already bankrupt anyway. Cheap and worthless is better than expensive and worthless.
Was I yelling at him? In my own head, I wasn't. I wasn't being mean to him in any way about any thing. Just reminding him to try and fix it.
Y'all are so touchy these days... I don't remotely imagine he can fix everything he said he would fix, to begin with, nor do I expect him to be able to do it immediately.
I know kid, I was just messing with your head. That's why I put the phrase "more seriously" at the beginning of the next paragraph.
Hey, it's the free market, what the hell if they can't afford the drug that's their problem.../s
Sadly that's how it goes. Government control drug prices in Europe that's why they are so much cheaper. Damn socialism...saving lives and allowing people to be able to purchase the drug at a reasonable price.
It is disgusting!
Why is that disgusting? We pay for the D&R, the students do most of the work at universities for fee, the rest of the world will only buy at fixed cost, but the American consumer pays through the nose. That is what is disgusting. We don't need a gov provider, but what we do need is a max out formula that they can charge. Believe me, they will still make money.
I doubt they'd make much money on a drug that << 200k people could use. Nobody is going to research and market such a niche product.
A simpler question is why couldn't the FDA simply accept the European tests for the drug? Then this company wouldn't have to pay big bucks to reinvent the wheel.
People who suffer from diseases of less than 200K are already ignored. This disease group is called "orphan diseases", and there is very little research done on them. ALS used to be among these diseases, until the research labs found that it belonged to a larger group of diseases. Since then a decent amount of money has been spent, with the bulk of the research going on at campuses like Columbia and Hopkins.
Perrie, that would require a 'tyrannical' governmental intervention. Conservatives and 'tyranny' mix like oil and water.
In NYC, they use a formula to fix the prices of apartments. They meet once a month with the exception of the annual hearing of landlords and tenants. It is a very minimal intervention.
I hear the rent is outrageous. It's not working is it?
You can rent in one of the nicest towns in the country Aspen, Co. for less.
The rent is too damn high.
It affects fewer and fewer apartments.
There is a difference between rent controlled and rent stabilized. I am talking about rent stabilized.
We are wayyyy beyond that. Imagine if the prices of New York apartments had reached $150,000 per month before a committee was formed to address the issue. The change that needs to happen is tyrannical at this point. There are private sector healthcare industries that need to learn to thrive on a fraction of what they are accustomed to, if we want to truly correct this situation.
I agree Hal, that we are in need of serious correction. How it should be done, is what I am not sure of.
In NYC, they use a formula to fix the prices of apartments. They meet once a month with the exception of the annual hearing of landlords and tenants. It is a very minimal intervention.
How's that working out Perrie? I don't know if I agree with it being so beneficial. Not arguing, but the way I see it, a person paying a $1000 a month for an apartment isn't getting too much and can't afford to move because the new apartments down the road are 5 times as expensive, but they aren't 50 years old and the landlord is trying to fill them, not run the tenets out like it happens with a lot of those old buildings, so people can't move up, but have to move away instead.
Those landlords who own the old buildings and apartments would like nothing more than for them to burn to the ground so they can replace then with a new building and make 5 to 10 times as much. Some of those people still live in the apartment their parents lived in and their rent is very low compared to the same apartment if it was new, so the landlord is seeing how much he is losing and can't do anything about it, but provide poor service. Now some would say they get all over them for providing bad service, but usually those people don't live in them.
Sometimes I think it would be better for everyone to get yearly increases so the landlords of the older buildings don't feel like they need to get rid of that old building and replace it with a new one.
That is what I said.....disgusting! Did I spell the word disgusting wrong?
OK what is disgusting are the prices Americans pay big pharm. See, now I fixed it for you.
My blood pressure medicine was about $7 per month until I satisfied my deductible. Now it's a $20 copay...
Something isn't right there, Cerenkov. Once I satisfied my deductible, back in Sept., my meds were free up to copay of $7. Of course, I was $3000 out of pocket to reach that point.
It's pretty obvious why many people go to Canada to purchase their pharmaceuticals. We saw it with the epi-pen, and now this.
I agree Buzz. My friend is a pharmacist in Windsor, Ontario, and he gets a ton of business from the Detroit area.
Let's see $89,000 divided by 70 equals $1,271.42
Buy yours from Sixpick's Discount Drug Pharmacy.
May take a little longer, but the savings are worth it!!!